Abstract. As 20% of stage I NSCLC patients develop recurrent and often incurable cancer, the identification of prognostic markers has a meaningful clinical application. The biological significance of steroid hormone and EGF receptors, able to regulate key physiological functions, remains elusive in NSCLC. Our aim was to investigate the prognostic input of estrogen receptors (ER·, ERß), progesterone receptors (PR) and EGFR in tumors from 58 stage I NSCLC patients. Antigen expression was analyzed by immunohistochemistry. Prognostic evaluation was performed with the multivariate Cox model. We found that about 70 and 40% of samples expressed ER· or ERß at cytoplasmic or nuclear level, respectively. Besides, only 12.1% of samples weakly expressed nuclear PR and 62.7% showed membrane EGFR staining. Correlation studies indicated an inverse association between EGFR expression and smoking status (p<0.01). Multivariate studies showed that the lack of nuclear ERß or the loss of EGFR expression were independent prognosis markers associated with shorter overall survival. We also found that patients whose tumors were negative for these two biomarkers presented the worst outcome. In conclusion, our findings could be useful for selecting stage I NSCLC patients with poor prognosis to apply an earlier treatment that impacts on survival.
Introduction
Lung cancer is the leading cause of cancer death in developed countries. The age-standardized mortality rates (per 100,000) of this cancer for Argentina (period 1997-2001) were 35.0 and 6.7 cases in men and women, respectively, being the first cause of cancer-related death in men and the fourth in women (1) .
Lung cancer is histologically classified into small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). NSCLC accounts for approximately 80% of all cancer cases and represents a heterogeneous group which includes squamous cell carcinoma (SCC), adenocarcinoma (ADC) and large cell carcinoma. SCC is markedly associated with smoking and more frequently detected in males, but ADC tends to occur more frequently in females, suggesting a possible involvement of gender-dependent factors in the pathogenesis and/or development of NSCLC (2) .
Clinicians face some difficulties in the management of lung cancer patients. First, patient survival has been shown to be mainly dependent on the stage of the disease at the time of diagnosis, being the rate of incidence practically equal to the rate of death when NSCLC is diagnosed at advanced-stages. It is also known that 20% of stage I and 30% of stage II patients develop recurrent cancer which is often incurable at the time of discovery. Second, few clinical factors are useful for assessing individual prognosis which are insufficient to predict the evolution of each patient (3) . In this scene, it is of high priority to find tumoral markers able to identify a subset of patients with poor prognosis in order to apply an earlier therapy that may have impact on survival.
Among the key molecules able to regulate physiological cellular functions and modulate tumor progression are the steroid hormones. Their effects are mediated by specific receptors, belonging to the nuclear hormone receptors superfamily, which modulates the expression of genes involved in cell proliferation, apoptosis, invasion, angiogenesis and metastasis (4) . There are two estrogen receptors, known as ERalpha (ER·) and ERbeta (ERß), that can induce different biological responses (5) (6) (7) , modulating gene expression in classical and non-classical ways (8) . In addition, recent studies have described non-genomic ER actions, originated at extranuclear sites. It is known that ERs are concentrated in caveolae and lipid rafts, regions highly enriched with critical signaling molecules as EGFR and HER2 (9) , and that membrane-initiated steroid signaling activity can result in ONCOLOGY REPORTS 24: 1331 -1338 , 2010 Estrogen receptor ß and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer activation of growth factor signaling pathways (10, 11) . Thus, in some tumors, estrogens could be acting as a dominant factor by activating multiple pathways important in tumor progression. On the other hand, ERs can also be activated by crosstalk with growth factor receptors such as EGFR and IGFR (insulin growth factor receptor) via receptor phosphorylation (12, 13) .
Progesterone receptor (PR) is codified by an estrogenregulated gene and its synthesis in normal and cancer cells requires estrogen and ER (14) . It is known that the activation of PR induces differentiation and inhibition of cellular proliferation (15) .
The expression of sex steroid receptors has been previously reported in non-traditionally estrogen responsive malignancies, such as osteosarcoma, hepatocarcinoma, colorectal, renal and pancreatic cancer (16, 17) as well as in NSCLC (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . However, their biological significance remains unclear.
The EGFR (HER-1 or erbB-1) is a transmembrane tyrosine kinase receptor that, in response to different ligands, can dimerize and mediate a series of signaling cascades via phosphorylations that culminate in the regulation of transcription factors and other proteins that control cell fate (31) . The EGFR is mutated or overexpressed in many human cancers, including NSCLC tumors, and this often correlates with a more aggressive disease (32) . This fact has been determinant for the approval of the EGFR receptor kinase inhibitor for clinical use in the treatment of advanced NSCLC as monotherapy following failure of chemotherapy (33) . Furthermore, the crosstalk between EGFR and ER pathways in lung cancer could provide a rationale to combine inhibitors of EGFR activation with anti-estrogen therapy for the treatment of the disease (9, 34) .
As the relationship between sex steroid receptors and EGFR has been poorly studied, our aim was to analyze the expression pattern of ER·, ERß, PR and EGFR in the primary tumor of a group of 58 patients with localized (stage I) NSCLC. Results were correlated with clinical and anatomo-pathological parameters accepted as established prognostic factors, including survival rate. All patients who died (n=14) had clear evidence of uncontrolled tumor growth at the time of death. This was assessed by different procedures carried out for each patient: computerized axial tomography and/or nuclear magnetic resonance (14/14) and confirmatory biopsy (2/14).
Materials and methods

Patients
The median follow-up for this homogeneous cohort was 48 months, with a range from 3 to 116 months.
The Ethic Committees of the Institute of Oncology 'Angel H. Roffo' and the 'Hospital Italiano de Buenos Aires' approved this study, having carefully followed the Helsinki Declaration.
Immunohistochemistry (IHC).
Tumor specimens were fixed with 10% formaldehyde in phosphate-buffer solution (PBS) immediately after removal and processed to paraffin blocks. Representative serial sections (5 μm thick) were placed on positively charged glass slides and microwaved in citrate buffer (pH 6.0) to recover antigenicity. Sections were treated with 7% hydrogen peroxide in methanol for 20 min to block endogenous peroxidase activity. Then, sections were incubated with 5% milk in distilled water for 45 min to block nonspecific binding and incubated overnight at 4˚C with the following commercial primary antibodies: two different anti-ER·: NCL-ER-6F11 (Novocastra, Newcastle, UK) and sc543 (Santa Cruz Biotechnology, USA, which recognizes the COOH terminal of the ER), anti-PR (sc 539, Santa Cruz Biotechnology) and the monoclonal mouse anti-human Table I . Clinico-pathological data of patients with NSCLC (n=58). 
Where columns do not sum to the total, data were missing or unknown.
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EGFR (EFGR PHARM Dx K1494, Dako, USA). Anti-ER· and PR were used at 1/100 dilution in PBS, anti-ERß was used at 1/200 and anti-EGFR was used without dilution. Then, sections were incubated 1 h at room temperature with biotinylated anti-mouse or anti-rabbit antibody, according to the species of the first antibody (Gibco-BRL, Gaithersburg, USA). In the case of ERß a chicken polyclonal antibody was employed and it was a gift from Dr J.A. Gustafsson (Sweden). After washing, sections were treated with Vectastain ABC kit Universal (PK-6200, Vector Laboratories, Burlingame, USA) and then incubated with the chromogen 3,3'diaminobenzidine (DAB).
Finally, they were counterstained with Harris hematoxylin. Negative controls, missing out the first antibody or incubating with primary not related antibodies, were performed to discriminate background staining.
Besides, a breast cancer sample positive for ER and PR was always included as a positive control. The expression of the different antigens in NSCLC tumors was analyzed by three independent observers and was scored according to the number of positive cells with specific bright brownish staining. Disagreements in scorings (about 8%) were resolved by revision and discussion with a multiheaded microscope.
Pathologists were blinded to all subject characteristics and survival status.
Review of paired normal and tumor tissue was difficult because of the lack of adjacent normal tissue in most blocks. Differences in the intensity of staining were not considered.
The labeling index for each antigen was calculated as the percentage of labeled cells out of the total number (n=1500) of tumor cells counted. For statistical analysis, scores were later dichotomized to a score of 'negative' or 'positive' staining. For cytoplasmic or membrane staining a value of 10% was required before a case was accepted as positive. In the case of nuclear staining the threshold was 5%, as in our series only a low percentage of nuclei were specifically labeled.
Statistical analysis. We analyzed the relationship between the expression of the different antigens and known prognostic factors in lung cancer: sex, age, histological type, tumor size (T), type of surgery (pneumonectomy, segmentomy, lobectomy, bilobectomy) and smoking habit. For these analyses we used ¯2 and Fisher's exact test (when size was <5). The Spearman test was used for correlation analysis. A difference of p<0.05 was considered as significant.
The Kaplan-Meier method was used to estimate survival, defined as the time between tumor diagnosis and the patient's death or last contact in five years. In univariate survival analyses, two-sided log-rank test (LR) for equality of survivor functions were used to assess the prognostic significance of different parameters on antigen positivity.
In order to identify factors associated with antigen positivity, we controlled potential confounders (such as age, sex, tumor size, histology and smoking habit) employing logistic regression.
Multivariate analysis was performed using the stepwise Cox proportional hazards model to evaluate the predictive power of each variable independently of the others. We used a model starting with the Cox model containing all variables and successively eliminating the least statistically significant variable until only statistically significant variables were left (p<0.05). All variables were entered in the multivariate analysis as categorical ones. SPSSPC+ (version 11) for Windows software was used for the aforementioned analyses.
Results
Expression of receptors for steroid hormones and for EGF in NSCLC tissues.
The expression of ER· and ERß were studied in 58 NSCLC samples from stage I patients who had undergone surgery as monotherapy. Specific subcellular staining, at nuclear and cytoplasmic level, was independently recorded. In the case of ER·, two different antibodies were employed to immunostain the lung cancer tissue, but only the anti-ER· able to recognize the COOH-terminal epitope, stained the paraffin-embedded sections of lung tumors in a specific way.
As shown in Table II , we found that about 65-70% of NSCLC samples expressed ER· or ERß at cytoplasmic level, while 37.9 and 39.7% of them expressed nuclear ER· or ERß respectively. Next, we analyzed the number of NSCLC tissue samples that expressed ER· or ERß, independently of their subcellular localization (defined as total ER· or total ERß expression). As shown in Table II , a high percentage of samples (about 75%) showed staining for total ER· or total ERß. Conversely, we determined that a high percentage of NSCLC samples stained for at least one ER isoform at nuclear level (nuclear ER·/ß) (13.8% expressed both receptors, 50.0% presented one of the ER and 36.2% were completely negative for nuclear ER·/ß).
Regarding the expression of PR, we found that only 12.1% (7/58) of NSCLC samples showed nuclear staining, while PR expression at cytoplasmic level was not found in any sample. When EGFR expression was analyzed, 36/58 tumors (62.1%) showed staining of tumor cells at membrane level.
As biological interactions have been described for most of these molecules, we next analyzed whether there was any correlation with statistical significance between the levels of expression of the different molecules and according to their ONCOLOGY REPORTS 24: 1331 -1338 , 2010 Table II. Immunostaining of NSCLC tumors against ER· and ERß according to their subcellular localization. 
A weak, although significant association between the expression of nuclear ER· and cytoplasmic ER· was observed, employing a bivariate correlation test (Spearman test, p<0.05). In addition, a significant correlation between the expression of ER· and ERß at cytoplasmic level was found (Spearman test, p<0.01). On the contrary, there was no association between the expression of ER· and ERß at nuclear level.
The expression of EGFR did not correlate either with PR or ER· immunostaining, at any localization. However, we found a weak, although significant, association between EGFR and nuclear ERß expression (Spearman test, p<0.05).
Association between the expression of steroid and EGF receptors and relevant clinico-pathological features in lung cancer. Possible relationships between antigen immunostainings and clinicopathological features relevant in the prognosis of NSCLC patients were summarized in Table III . Cytoplasmic ER· expression was associated with tumor size (86.4% in T1 tumors vs. 61.1% en T2, ¯2, p=0.04). Besides, statistic analysis indicated that cytoplasmic ER· was found more frequently in ADC than in SCC tumors (¯2 p<0.05).
However, logistic regression indicated that this association disappeared when other prognostic factors were included in the multivariate analysis (data not shown). We also found that nuclear immunostaining for ER· expression decreased with age (Spearman test, p<0.001).
No statistically significant association was found between total ER·, total ERß, nuclear ER·/ß or PR status and sex, age, histology, tumor size, differentiation grade or smoking habit. Finally, we found that EGFR expression was associated with smoking habits (Spearman test, p<0.01).
Uni-and multivariate analysis between the expression of steroid and EGF receptors and overall survival. Univariate analysis indicated that the lack of nuclear ERß was associated with bad prognosis (Fig. 1) . Multivariate Cox analysis confirmed that this association maintained the statistical significance when other prognostic variables in lung cancer were included. Table IV shows the final model, with the variables that have shown to be significant.
The absence of membrane EGFR expression was also associated with a worse outcome, as shown in Fig. 2 . Multivariate Cox final model showed that this association was Table III . ER·, ERß, PR and EGFR expressions according to the main features with clinical relevance in lung cancer. 
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independent of other prognostic variables relevant in NSCLC (Table V) . On the other hand, the expression of ER· at any subcellular localization, cytoplasmic or total ER·, nuclear ER·/ß or PR did not seem to be relevant as prognosis factors of global survival, in this population of stage I NSCLC patients (data not shown). Next, NSCLC patients were sub-classified according to the expression of both molecules: nuclear ERß and/or EGFR, to determine whether the combination of both biomarkers could be a better predictor of survival than each one separately. NSCLC tumors negative for both, nuclear ERß and EGFR were defined as 'double negative tumors'. Univariate analysis showed a significant correlation between global survival and the expression of nuclear ERß/EGFR (LR test 8. 15 
Discussion
Some studies support the concept that sex steroid and EGFR receptors have key roles in normal lung biology and also in lung cancer (31, 35) . Our specific aim was to study the expression of sex steroid receptors (ER·, ERß and PR) and EGFR in NSCLC tumor in a cohort of stage I patients that had undergone surgical resection of their tumors, as monotherapy, and to determine whether their expression correlated with lung cancer clinico-pathological features and with overall survival. This population of stage I NSCLC patients seems to be representative, since survival studies demonstrated that male gender and large tumor size, known bad prognosis factors, were associated with a worse outcome (data not shown).
Here, we report new findings that may contribute to the clinical management of stage I NSCLC patients. Our results can be synthesized in three main points: i) a high percentage Table IV . Cox survival model for ERß expression in stage I NSCLC patients, taking into account the known prognostic clinico-pathological parameters in lung cancer. 
The variables entered in the multivariate analysis were age, sex, tumor size, histological type, type of surgical and smoking habit. The table shows the significant variables in the equation of nuclear ERß. Both the histological type and the tumoral size showed a relative risk of about 4.5 with a borderline significance, p<0.07 and 0.06 respectively. Reference values: sex, male; smoking habit, smoker; nuclear ERß, negative expression.
- ---------------------------------------------------------------------------------------------------- of tumors expressed both ER (· and ß) and EGFR receptors; ii) the lack of EGFR and nuclear ERß expression could be considered independent markers of poor outcome; and iii) the simultaneous lack of EGFR and nuclear ERß seems to be a better predictor of prognosis than each biomarker independently.
Previous studies support the selection of these molecules as possible prognosis biomarkers. It is nowadays accepted that estrogens are relevant in the homeostasis of the lung and may have a role in initiating and maintaining the growth of lung cancer (28, 36) . In addition, recent studies have provided evidence about a functional interaction between ER and EGFR pathways in different tissues, including lung cancer (34, 37) . In this sense, it was proved that the combined targeting of ER and EGFR in NSCLC cells showed higher antiproliferative effects than those obtained independently (34) .
As it is now accepted that ERs are functional both at nuclear and extranuclear level (12, 38) , we recorded ER expression at nuclear and cytoplasmic localization in an independent way in our NSCLC samples. We demonstrated, employing an immunohistochemical technique, that NSCLC tumors expressed both isoforms of estrogen receptors ER· and ERß. In the case of nuclear ER staining, we found that about 38-40% of tumors presented ER· or ERß immunopositivity. However, if we consider the expression of both receptors at nuclear level, about 64% of the samples showed at least one of these two isoforms. On the other hand, in the present study, we observed that extranuclear expression of ER occurs frequently, as we found cytoplasmic ER· and ERß immunoreactivities in 64-70% of NSCLC tumors. Only a few studies have reported extranuclear immunostaining (21, 26, 30) , being our results similar to those reported by Marquez-Garbán et al (26) regarding the levels of nuclear and extranuclear ER· and ERß expression. Our observations did not agree with those of other authors (21, 28) , who reported that ER· was located primarily in the cytoplasm, while ERß was probably the predominant nuclear receptor of normal lung and cancer samples.
There is discrepancy in the literature regarding the percentage of samples that express ER·. While some authors have detected little or no expression of ER· (19, 23) , others, as we did, have found staining for ER· in a high number of lung cancer tumors (26, 30) . In fact, the finding that specific immunostaining was obtained only when we employed an anti-ER· raised against epitopes in the -COOH terminus could explain the differences among different authors. Other studies also report that, in the case of lung tissues, no or little reactivity to ER· was observed when an antibody against the -NH2 terminus was used (21) . An explanation for this could be that the antibody recognizes epitopes in exons that are deleted in ER· (39) or that the antibody recognizes a conformation of the ER· protein specific for other tissues such as breast, but absent in the lung.
In the case of ERß most of the studies showed some degree of expression for this isoform (19, (22) (23) (24) (25) (26) (28) (29) (30) , suggesting its predominance in the lung.
We did not find any association between the expression of ERs and gender, similar to Marquez-Garbán et al (26) , while other authors reported that the expression of ERs in lung cancer is gender-dependent (19, 29) .
We also analyzed the expression of PR in the same group of lung cancer cases. PR immunoreactivity was detected only in the nuclei of NSCLC cells in a limited number of cases. Methodological aspects could explain the differences between our results and those of other authors who found either no reactivity (20) or up to about 63% of PR expression in NSCLC tumors (30) .
On the other hand, as the EGF receptor family including HER1 and HER2 is implicated in lung cancer pathogenesis and progression (31) and as EGFR antibodies or tyrosine kinase inhibitors impair the growth of lung tumors expressing ----------------------------------------------------------------------------------------------------- The variables entered in the multivariate analysis were the same as those indicated in the legend of Table IV. The table shows - ---------------------------------------------------------------------------------------------------- these receptors (40), we also analyzed the expression of EGFR (HER1). We found that more than 60% of the samples showed specific EGFR staining at membrane level (≥10% of positive cells). Several studies have analyzed the expression of EGFR in lung cancer, finding overexpression, defined in general as higher than 10% of immunopositive cells, in 13-80% of the cases (41) (42) (43) .
There are some studies examining ER· and ERß expressions as prognostic factors in terms of overall survival in NSCLC (19, 21, 25, 30) . In the present study we determined that the lack of nuclear ERß was associated with bad prognosis. Interestingly, this receptor has been related with antiproliferative effects (44) . In coincidence with us, Kawai et al found that the absence of ERß could be an independent factor predictive of poor disease outcome (21) . In addition, Schwartz et al found that lack of nuclear ERß expression was associated with worse survival, but only in a male population with lung cancer (19) . We did not find any correlation between the expression of ER· and prognosis, contrarily to Kawai et al who found that its overexpression was associated with poor outcome (21) . In addition, Raso et al found that the expression of ER did not correlate with overall survival, although they found that cytoplasmic overexpression of ER·4 was associated with worse recurrence-free survival (30) . Our study also determined that PR status was not useful to predict the outcome of the NSCLC patients, similar to Raso et al (30) . Another study reported that the lack of PR was strongly associated with better clinical outcome in a population that includes all TNM stages (18) .
Regarding EGFR, we found that its lack is an independent factor of poor prognosis in our population of stage I NSCLC patients. This result contrasts with those of other reports, as most of them found that EGFR is not a prognostic factor in NSCLC, while a small percentage associated EGFR overexpression with poor outcome (32, 43, 45) . In agreement with us, Rusch et al found that low EGFR expression was associated with worse overall survival in a univariate study (46) .
As previously mentioned, it is now known that sex steroid hormones establish crosstalk with growth factor-signaling pathways, such as those generated by activated membrane receptors of the HER family (34) . Taking into account that, in our population, both the lack of ERß and of EGFR was associated with poor prognosis, we analyzed the power of double negativity (nuclear ERß -and EGFR -) on patient survival. We found that early stage NSCLC patients with double negative tumors are at a higher risk of death and that this condition seems to predict the patient outcome in a better way than each biomarker individually. Interestingly, all double negative stage I NSCLC cases who died were also PR negative. However, due to the small number of positive PR tumors found, further studies are necessary to confirm this observation. In a similar way, in the last decade, several breast cancer subgroups that differ in their overall geneexpression profile were defined. One of them, the triplenegative phenotype, characterized by a lack of HER2 gene amplification (a molecule of the same family of receptors that EGFR) and a lack of estrogen and progesterone receptors expression, has the worst prognosis (47) .
In conclusion, our analysis of sex steroid and EGFR receptors in stage I NSCLC suggests that this tumor could be potentially considered a hormone responsive tissue. So, the anti-estrogen treatment, combined with the targeting of EGFR, could be an interesting therapeutic option, that was explored by Traynor et al in a clinical pilot study (48) . We have also demonstrated that lack of nuclear ERß and membrane EGFR immunostaining could be useful independent markers of poor global survival for stage I NSCLC patients. In addition, double negativity seems to be a better indicator to predict outcome than each biomarker individually. Although our study adds new information about lung cancer, we are aware of its limitations given the fact that the number of patients studied was not enough to detect strong associations when examining subgroups. However, we consider that our series is not dismissible, taking into account that it is a relatively large homogeneous population for a country without lung cancer screening programs and where the vast majority of patients are diagnosed at stages III or IV. It is our wish that, after validation in other oncology centers, the introduction of these molecular marker assessments into routine clinical management of NSCLC, is eventually made.
